Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNAs: role and therapeutic targets in viral hepatitis.
van der Ree MH, de Bruijne J, Kootstra NA, Jansen PL, Reesink HW. van der Ree MH, et al. Among authors: reesink hw. Antivir Ther. 2014;19(6):533-41. doi: 10.3851/IMP2766. Epub 2014 Mar 18. Antivir Ther. 2014. PMID: 24642660 Review.
Novel therapies in hepatitis B and C.
Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Takkenberg B, et al. Curr Gastroenterol Rep. 2008 Feb;10(1):81-90. doi: 10.1007/s11894-008-0013-z. Curr Gastroenterol Rep. 2008. PMID: 18417047 Review.
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H. de Bruijne J, et al. Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078. Epub 2012 Mar 16. Antivir Ther. 2012. PMID: 22427481 Clinical Trial.
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM, Hansen BE, van Vliet AA, van de Wetering de Rooij J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Reesink HW, de Knegt RJ, Janssen HL. Boonstra A, et al. Among authors: reesink hw. Antivir Ther. 2012;17(4):657-67. doi: 10.3851/IMP2023. Epub 2011 Dec 19. Antivir Ther. 2012. PMID: 22301364
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW. van der Ree MH, et al. Among authors: reesink hw. Antiviral Res. 2014 Nov;111:53-9. doi: 10.1016/j.antiviral.2014.08.015. Epub 2014 Sep 8. Antiviral Res. 2014. PMID: 25218783 Clinical Trial.
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: reesink hw. Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11. Lancet. 2017. PMID: 28087069 Clinical Trial.
Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
Jansen L, Welkers MRA, van Dort KA, Takkenberg RB, Lopatin U, Zaaijer HL, de Jong MD, Reesink HW, Kootstra NA. Jansen L, et al. Among authors: reesink hw. Antiviral Res. 2017 Sep;145:87-95. doi: 10.1016/j.antiviral.2017.07.013. Epub 2017 Jul 25. Antiviral Res. 2017. PMID: 28754258 Free article.
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: reesink hw. Antiviral Res. 2017 Oct;146:139-145. doi: 10.1016/j.antiviral.2017.08.016. Epub 2017 Aug 24. Antiviral Res. 2017. PMID: 28844749 Free PMC article.
353 results